Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 5/20 | 0.55 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2E1 | P05181 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | CYP4B1 | P13584 | 3/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.47 |
| ▸ | CYP3A5 | P20815 | 3/20 | 0.47 |
| ▸ | CYP2A7 | P20853 | 3/20 | 0.47 |
| ▸ | CYP3A7 | P24462 | 3/20 | 0.47 |
| ▸ | CYP2F1 | P24903 | 3/20 | 0.47 |
| ▸ | CYP2C18 | P33260 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.47 |
| ▸ | CYP4F8 | P98187 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32663058 | 0.82 | CYP1A1 (0.55) | CYP1A1CYP1B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL27930044 | 0.81 | DYRK1A (0.56) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL16668505 | 0.79 | CYP1A1 (0.47) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL1735138 | 0.79 | PDGFRB (0.49) | NPC1RAB9AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL459802 | 0.77 | — | — | |
| SCHEMBL2954516 | 0.76 | ALDH1A1 (0.79) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL29385373 | 0.76 | CYP1A1 (0.43) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL16667819 | 0.76 | CYP1A1 (0.43) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL15244319 | 0.75 | MAOB (0.43) | CYP1A1CYP1B1ALDH1A1NPC1RAB9A | |
| SCHEMBL15413000 | 0.75 | FGFR4 (0.53) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113402-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | SUI ZHIHUA (US) | 2005-05-26 | — | — | US | disclosed |
| US-6818646-B2 | 1,2,3,4-TETRAHYDRO-2-(5-(2-PYRIDINYL)-PYRIMIDIN-2-YL)-3-(2,3 -DIHYDROBENZOFURANYL)-9H-PYRROLO-(3,4-B)QUINOLIN-9-ONE; MALE ERECTILE DYSFUNCTION; SEXUAL DISORDERS | SUI ZHIHUA (US) | 2004-11-16 | — | — | US | disclosed |
| EP-1296981-B1 | SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040044021-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | SUI ZHIHUA (US) | 2004-03-04 | — | — | US | disclosed |
| US-6635638-B2 | Treatment of sexual dysfunction, cardiovascular system disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1296981-A2 | SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020072055-A1 | Iterative and regenerative DNA sequencing method | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2002-06-13 | — | — | US | disclosed |
| US-20020010183-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-24 | — | — | US | disclosed |
| WO-2001087882-A2 | SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113402-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | CYP1A1 582/4885CYP1B1 143/4885CYP1A2 156/4885 |
| US-20040044021-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | CYP1A1 407/4885CYP1B1 101/4885CYP1A2 143/4885 |
| US-20020010183-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | CYP1A1 407/4885CYP1B1 101/4885CYP1A2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.